Vascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.

TitleVascular morphology differentiates prostate cancer mortality risk among men with higher Gleason grade.
Publication TypeJournal Article
Year of Publication2016
AuthorsYang M, Zu K, Mucci LA, Rider JR, Fiorentino M, Clinton SK, Loda M, Stampfer MJ, Giovannucci E
JournalCancer Causes Control
Volume27
Issue8
Pagination1043-7
Date Published2016 08
ISSN1573-7225
KeywordsAdult, Aged, Humans, Male, Middle Aged, Neoplasm Grading, Neovascularization, Pathologic, Prognosis, Prostate, Prostate-Specific Antigen, Prostatic Neoplasms, Risk
Abstract

BACKGROUND: Higher Gleason grade is associated with prostate cancer mortality; however, there is significant heterogeneity in this association. We evaluated whether vessel morphology, a biomarker of angiogenesis, aided in distinguishing mortality risks among men with high Gleason grading.

METHODS: We characterized vessel morphology (area and irregularity) among 511 patients diagnosed with prostate cancer during 1986 to 2000, re-reviewed Gleason grade, and followed men through 2012. Men were grouped according to integrated vessel lumen irregularity and vessel area across Gleason grade. The more angiogenic group was identified as those with more irregular vessel lumen and smaller vessel area. Crude rates (95 % confidence intervals) and survival probability were estimated across Gleason grade and vessel morphology.

RESULTS: During a median 14-year follow-up, 62 men developed bone metastases or died of prostate cancer. Lethality rates were uniformly low within Gleason grade categories 6 and 7(3 + 4), regardless of vessel morphology. However, among men with Gleason grades of 7(4 + 3) or 8-10, the more angiogenic group was associated with fourfold higher risk of lethal outcomes compared to those with less angiogenic potential. Ten-year survival probability ranged from 95 to 74 % according to the extent of vessel morphology (p < 0.0001, log-rank test).

CONCLUSIONS: Vessel morphology may aid Gleason grading in predicting prostate cancer mortality risks among men diagnosed with high-grade Gleason cancers.

DOI10.1007/s10552-016-0782-x
Alternate JournalCancer Causes Control
PubMed ID27379990
PubMed Central IDPMC4958547
Grant ListP50 CA090381 / CA / NCI NIH HHS / United States
P01 CA087969 / CA / NCI NIH HHS / United States
P01 CA055075 / CA / NCI NIH HHS / United States
R01 CA133891 / CA / NCI NIH HHS / United States
P30 CA016058 / CA / NCI NIH HHS / United States
UM1 CA167552 / CA / NCI NIH HHS / United States
R01 CA141298 / CA / NCI NIH HHS / United States
Related Faculty: 
Massimo Loda, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700